In Brief: Pharmanex
This article was originally published in The Tan Sheet
Executive Summary
Pharmanex: Withdraws complaint against FDA seeking court declaration that cholesterol-lowering claims for its Cholestin dietary supplement are appropriate under the Dietary Supplement Health & Education Act and are not unapproved new drug claims. The complaint was filed in Salt Lake City, Utah federal court April 7 ("The Tan Sheet" April 14, p. 1). FDA filed a motion to dismiss the complaint April 30 on the basis that the matter was not "ripe for review" ("The Tan Sheet" May 12, In Brief). Pharmanex' motion to voluntarily dismiss the action "without prejudice" is dated May 8. The company and FDA are in discussions regarding the agency's position that the claims are inappropriate...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning